FDA Approves Kura Oncology Leukemia Drug, Teeing Up Competition With Syndax Pharma
Kura Oncology’s Komzifti is approved for treating advanced cases of acute myeloid leukemia with an NPM1 mutation. A Syndax Pharmaceuticals drug is already approved in this indication, but Kura says its drug has advantages in safety and patient convenience.